On June 1, RemeGen fell 5.08% in regular trading, trading at HKD 78.1/share, with trading volume of HKD 307 million.

The decline was driven by escalating US-China biotech regulatory tensions. US lawmakers recently proposed incorporating biotechnology into the COINS Act restricted list, aiming to limit American capital flows into Chinese innovative drug companies. The proposal directly cited major cross-border BD transactions as justification, noting that Chinese companies accounted for 48% of global licensing deals above $50 million in recent years, up from zero in 2020. Simultaneously, market reports indicated that Chinese regulators may impose pre-approval requirements on overseas BD transactions involving antibody, targeted therapy, small nucleic acid, and cell-gene therapy technologies.

These dual regulatory barriers have undermined the core valuation logic for Chinese biotech companies, where overseas BD expectations serve as the primary valuation anchor. Additionally, Oriental Securities recently reduced its RemeGen holdings by 160,000 shares at an average price of HKD 84.83, while ETF funds tracking the stock recorded cumulative net outflows of RMB 162 million over 60 days, reflecting broader capital rotation away from the sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)